MG
NTLA icon

Marex Group’s Intellia Therapeutics NTLA Stock Holding History

Marex Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Hold
623,600
– – 0.04% 174
2026
Q1 		$7.99M Sell
623,600
-1
-0% -$13 0.05% 179
2025
Q4 		$5.61M Buy
623,601
+1,001
+0.2% +$13.8K 0.04% 206
2025
Q3 		$10.8M Sell
622,600
-1,000
-0.2% -$12.3K 0.08% 141
2025
Q2 		$5.85M Buy
+623,600
New +$5.12M 0.05% 161

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Marex Group's NTLA Position: Q2 2026 in Review

Marex Group held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 623,600 shares worth $10.6M. The position accounts for 0.04% of the portfolio, ranked #174.

Marex Group first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.8M in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Marex Group held 623,600 shares of Intellia Therapeutics worth $10.6M as of Q2 2026.
  • Marex Group left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up 0.04% of Marex Group's portfolio in Q2 2026, its #174 holding.
  • Marex Group first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Marex Group's Intellia Therapeutics position peaked at $10.8M in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.